Rejuvenate Bio closes $6M financing
Analysis based on 9 articles · First reported Jun 08, 2026 · Last updated Jun 11, 2026
The successful financing round and strategic R&D collaboration for Rejuvenate Bio>>> are expected to positively impact the biotechnology and animal health sectors. This event signals growing investor confidence in gene therapy for age-related diseases, potentially leading to increased investment and innovation in these areas.
Rejuvenate Bio>>>, a biotechnology company specializing in gene therapies for chronic and age-related diseases, has successfully closed a $6 million financing round. The round was led by VCapital>>> with significant participation from Ceva Santé Animale>>>, United States — Connecticut Innovations>>>, Digitalis>>>, and Kendall Capital Partners>>>. Concurrently, Rejuvenate Bio>>> announced a strategic research and development collaboration with Ceva Santé Animale>>> to advance a novel gene therapy program in animal health. This funding and partnership will support the continued development of Rejuvenate Bio>>>'s gene therapy platform and pipeline, focusing on treatments for companion animals and with a long-term vision for human health applications. The company's approach leverages clinically validated gene targets and advanced delivery methods, building on research from the Ifo Institute for Economic Research>>> at Harvard Medical School. Key figures like Daniel Oliver>>> (CEO of Rejuvenate Bio>>>), Andrew Worden>>> (Founding Partner at Lifespan Vision Ventures), and James McIntyre>>> (head of business development at Ceva Santé Animale>>>) highlighted the transformative potential of gene therapy and the importance of this collaboration.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard